Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
Daimler AG57,8258,212,54
05.12.2020 2:04:00
Indexy online
AD Index online
AD Index online

  • 04.12.2020 18:00:00
BioGaia (BIOGb.ST, Stockholm)
Závěr k 4.12.2020 Změna (%) Změna (SEK) Objem obchodů (SEK)
491,00 1,76 8,50 11 941 483
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

  • Poslední aktualizace: 05.12.2020
Popis společnosti
Obecné informace
Název společnostiBioGaia AB
TickerBIOG B
Kmenové akcie:Ordinary Shares Class B
Kmenové akcie:Ordinary Shares
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.09.2020
Počet zaměstnanců k 30.09.2020 160
Akcie v oběhu k 30.09.2020 17 336 462
Kontaktní informace
UliceKungsbroplan 3
PSČ112 27
Kontatní osobaAlexander Kotsinas
Funkce kontaktní osobyChief Financial Officer, Executive Vice President
Telefon46 855 529 300
Kontatní telefon460 735 001 111

Business Summary: Biogaia AB is a Sweden-based company engaged in the development and sell of probiotic products, primarily based on the Lactobacillus reuteri bacteria. The Company’s activities are divided into three segments: Finished consumer products, which distributes tablets, drops, Oral Rehydration Solutions (ORSs), and oral health products, among others; Component products, which is responsible for the sale of LifeTop Straw and Life Top Cap, as well as of cultures as an ingredient in licensee products, such as infant formula and dairy products; and Other products, including animal health goods. It collaborates with Nestle, Gerber, Delta Medical, InfectoPharmm, Ferring Middle East, AllergyCare, and Ewopharma, among others. Furthermore, the Company operates worldwide through a number of subsidiaries, such as Biogaia Biologics Inc, CapAble AB, TwoPac AB and Infant Bacterial Therapeutics AB.
Financial Summary: BRIEF: For the nine months ended 30 September 2020, BioGaiaAB revenues decreased less than 1% to SEK559.5M. Net incomeincreased 5% to SEK141.3M., also reflect EMEA segmentdecrease of 80% to SEK57.7M, Americas segment decrease of69% to SEK45.5M. Net income benefited from Selling Expensesdecrease of 5% to SEK122M (expense), Research anddevelopment expenses decrease of 8% to SEK75M (expense).
Odvětvová klasifikace
TRBC2012Special Foods & Welbeing Products
MGINDUSTRYFood Processing
NAICS2007Nonchocolate Confectionery Manufacturing
NAICS2007Dry/Condensed/Evaporated Dairy Product Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Non-Chocolate Confectionery Manufacturing
NAICS1997Dry, Condensed, and Evaporated Dairy Product Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCandy/other Confectionery Prod'Ts
SICDry/condensed/evaporated Products
SICCommercial Physical Research
SICPharmaceutical Preparations

  • Poslední aktualizace: 05.12.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardPeter Rothschild7025.04.2018
President, Chief Executive OfficerIsabelle Ducellier5105.11.2018
Independent Vice Chairman of the BoardDavid Dangoor7125.04.201824.04.2007
Chief Financial Officer, Executive Vice PresidentAlexander Kotsinas5305.11.201905.11.2019
Executive Vice President - SalesUrban Strindlov56
Executive Vice President of MarketingUlrika Kohler5401.01.2013
Executive Vice President - Business and Product DevelopmentSebastian Schroder4704.11.201801.01.2015
Vice President, General CounselMarika Isberg4701.01.2018
Vice President Human ResourcesAngelika Kjelldorff5101.01.2019
Vice President - Discovery and ResearchGianfranco Grompone4501.01.2020